Description
Patients and doctors often search for information regarding the Blinatumomab price in India to treat certain forms of Acute Lymphoblastic Leukemia (ALL). Blinatumomab, marketed as Blincyto, is a bispecific CD19-directed CD3 T-cell engager used in eligible adult and pediatric patients with specific ALL indications.
As of June 2026, Blinatumomab is not commercially marketed in India. Import is generally facilitated through international procurement under the Named Patient Program (NPP). The final procurement cost may vary depending on treatment protocol, dosage requirements, country of sourcing, international freight charges, regulatory documentation requirements, and cold-chain transportation arrangements.
Indian Pharma Network (IPN) supports hospitals, physicians, and eligible patients with compliant access to genuine Blinatumomab sourced from approved international supply channels.
For current pricing information, availability, and procurement assistance, contact our team directly.
Location
Noida-Greater Noida Expressway, Ansal Golf Links 1, Greater Noida, Uttar Pradesh 201310